JP2018023397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018023397A5 JP2018023397A5 JP2017194380A JP2017194380A JP2018023397A5 JP 2018023397 A5 JP2018023397 A5 JP 2018023397A5 JP 2017194380 A JP2017194380 A JP 2017194380A JP 2017194380 A JP2017194380 A JP 2017194380A JP 2018023397 A5 JP2018023397 A5 JP 2018023397A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- xbp
- peptide consisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 102000008165 X-Box Binding Protein 1 Human genes 0.000 claims 32
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 21
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims 16
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims 16
- 102100032831 Protein ITPRID2 Human genes 0.000 claims 16
- 210000002865 immune cell Anatomy 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5818008P | 2008-06-02 | 2008-06-02 | |
| US61/058,180 | 2008-06-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017013407A Division JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018214477A Division JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018023397A JP2018023397A (ja) | 2018-02-15 |
| JP2018023397A5 true JP2018023397A5 (enExample) | 2018-05-24 |
| JP6438100B2 JP6438100B2 (ja) | 2018-12-12 |
Family
ID=41398806
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512566A Withdrawn JP2011523560A (ja) | 2008-06-02 | 2009-06-01 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017194380A Active JP6438100B2 (ja) | 2008-06-02 | 2017-10-04 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512566A Withdrawn JP2011523560A (ja) | 2008-06-02 | 2009-06-01 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9096681B2 (enExample) |
| EP (2) | EP2300034B1 (enExample) |
| JP (7) | JP2011523560A (enExample) |
| CN (1) | CN102112147B (enExample) |
| CA (2) | CA3138282A1 (enExample) |
| WO (1) | WO2009149021A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102112147B (zh) | 2008-06-02 | 2014-05-21 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138、和cs1肽 |
| AU2013337247B2 (en) * | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| US10463750B2 (en) | 2013-02-15 | 2019-11-05 | The Johns Hopkins University | Antigen-Specific T cell redirectors |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| US10483541B2 (en) | 2016-05-09 | 2019-11-19 | Nichia Corporation | Method of producing nickel-cobalt composite hydroxide and method of producing positive electrode active material for non-aqueous electrolyte secondary battery |
| CN106093393A (zh) * | 2016-06-02 | 2016-11-09 | 滨州医学院 | 一种基于XBP1和XBP1s表达水平的检测胃癌组织的试剂盒 |
| EP3700575A1 (en) | 2017-10-24 | 2020-09-02 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| CN115040663B (zh) * | 2022-06-15 | 2023-12-12 | 上海交通大学医学院附属仁济医院 | 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| HK1001832A1 (en) | 1991-04-25 | 1998-07-10 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| DE69332485T2 (de) | 1992-08-11 | 2003-11-13 | The President And Fellows Of Harvard College, Cambridge | Immunmodulierende peptide |
| CA2153692C (en) | 1993-01-12 | 2011-11-08 | Roy R. Lobb | Recombinant anti-vla4 antibody molecules |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU6802801A (en) * | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| JP2005503118A (ja) | 2001-02-14 | 2005-02-03 | ジェンザイム・コーポレーション | 改変ペプチドリガンド |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US6979720B2 (en) | 2002-05-03 | 2005-12-27 | E. I. Du Pont De Nemours And Company | manufacture of certain cyclic ester oligomers |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| WO2005037855A2 (en) | 2003-10-17 | 2005-04-28 | Pecos Labs, Inc. | T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same |
| JP4758984B2 (ja) | 2004-03-29 | 2011-08-31 | アボット バイオセラピューティクス コーポレイション | 抗ｃｓ１抗体の治療的使用 |
| BRPI0514870A (pt) * | 2004-09-02 | 2008-06-24 | Wyeth Corp | sistemas e métodos para a produção de proteìna |
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| JP2010500370A (ja) * | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| CN102112147B (zh) | 2008-06-02 | 2014-05-21 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138、和cs1肽 |
| AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
-
2009
- 2009-06-01 CN CN200980130349.4A patent/CN102112147B/zh active Active
- 2009-06-01 WO PCT/US2009/045866 patent/WO2009149021A2/en not_active Ceased
- 2009-06-01 CA CA3138282A patent/CA3138282A1/en active Pending
- 2009-06-01 US US12/995,661 patent/US9096681B2/en active Active
- 2009-06-01 EP EP09759182.0A patent/EP2300034B1/en active Active
- 2009-06-01 JP JP2011512566A patent/JP2011523560A/ja not_active Withdrawn
- 2009-06-01 CA CA2726804A patent/CA2726804C/en active Active
- 2009-06-01 EP EP18162674.8A patent/EP3384919A1/en active Pending
-
2014
- 2014-12-25 JP JP2014262194A patent/JP6085289B2/ja active Active
-
2015
- 2015-06-29 US US14/754,456 patent/US11083783B2/en active Active
-
2017
- 2017-01-27 JP JP2017013407A patent/JP6224280B2/ja active Active
- 2017-10-04 JP JP2017194380A patent/JP6438100B2/ja active Active
-
2018
- 2018-11-15 JP JP2018214477A patent/JP6796123B2/ja active Active
-
2020
- 2020-11-13 JP JP2020189192A patent/JP7321137B2/ja active Active
-
2021
- 2021-07-08 US US17/370,412 patent/US20220031821A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120931A patent/JP2023134812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018023397A5 (enExample) | ||
| JP2014240404A5 (enExample) | ||
| PE20251185A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| JP2015131795A5 (enExample) | ||
| JP2017165733A5 (enExample) | ||
| WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| JP2017048194A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| CL2019003426A1 (es) | Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| JP2014532649A5 (enExample) | ||
| JP2020511672A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| JP2016519933A5 (enExample) | ||
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2017511135A5 (enExample) | ||
| RU2021132734A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2015510393A5 (enExample) | ||
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| CN115666594A (zh) | Cart细胞在制备治疗癌症的药物中的应用 | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| JP2014502961A5 (enExample) |